CD19/CD22 CAR T-Cells
Cell therapy
CD19/CD22 CAR T-Cells is one of 46 biologic programs targeting Leukemia. It is currently in development.
1
Indications
3
Total Trials
2
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Leukemia
#DrugCompanyPhaseTrials
1Trexall
Alnylam PharmaceuticalsPhase 3
Fludara
SanofiPhase 3
Idamycin
PfizerPhase 3
Neoral
NovartisPhase 3
Decadron
AAspen Global Incorporated
Phase 3
Novantrone
PfizerPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Busulfex
Akero TherapeuticsPhase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD19/CD22 CAR T-Cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Company
- EEssen Biotech